Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Our organization by Business Unit boosts the quality of our active compounds
To boost the quality of each compound, our company has been organized into Business Units since January 2020. This organization also aims to make the Group’s activities clearer for employees, customers, partners and investors. Each BU has its own objectives and resources. They will naturally lead to subsidiaries in the coming years depending on their level of maturity.
"Oncodesign has been listed on Euronext Growth Market since April 2014 (ALONC, Paris). Our biggest goal since our creation has been to discover effective therapies to fight cancer and other diseases for which no treatment is currently available. We have built a unique platform ofprecision medicine dedicated to resistant or refractory diseases (...)"